Vetr lowered shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a strong-buy rating to a hold rating in a research report report published on Friday morning. Vetr currently has $14.26 price target on the specialty pharmaceutical company’s stock.

Several other research firms also recently issued reports on VRX. BMO Capital Markets reaffirmed a hold rating and issued a $15.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 27th. Zacks Investment Research raised Valeant Pharmaceuticals International from a strong sell rating to a hold rating in a research note on Thursday, July 27th. J P Morgan Chase & Co set a $10.00 price objective on Valeant Pharmaceuticals International and gave the company a hold rating in a research note on Monday, July 17th. Deutsche Bank AG set a $19.00 price objective on Valeant Pharmaceuticals International and gave the company a hold rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Five investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $17.71.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 13.39 on Friday. The company’s market cap is $4.67 billion. The stock has a 50 day moving average of $13.96 and a 200 day moving average of $13.57. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter in the prior year, the firm posted ($0.88) earnings per share. The firm’s revenue was down 7.7% compared to the same quarter last year. Equities research analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/vetr-inc-lowers-valeant-pharmaceuticals-international-inc-vrx-to-hold/1633967.html.

In other news, Director Schutter Richard U. De bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the acquisition, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.87% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Armstrong Henry H Associates Inc. lifted its holdings in shares of Valeant Pharmaceuticals International by 0.3% in the 2nd quarter. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company’s stock worth $1,622,000 after purchasing an additional 295 shares in the last quarter. Eaton Vance Management lifted its holdings in shares of Valeant Pharmaceuticals International by 1.2% in the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 500 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Valeant Pharmaceuticals International by 0.4% in the 2nd quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock worth $2,220,000 after purchasing an additional 509 shares in the last quarter. NEXT Financial Group Inc lifted its holdings in shares of Valeant Pharmaceuticals International by 6.2% in the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after purchasing an additional 600 shares in the last quarter. Finally, Tocqueville Asset Management L.P. lifted its holdings in shares of Valeant Pharmaceuticals International by 3.8% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 21,914 shares of the specialty pharmaceutical company’s stock worth $379,000 after purchasing an additional 800 shares in the last quarter. Institutional investors own 50.44% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.